Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
14 hedge funds and large institutions have $64.5M invested in Calliditas Therapeutics AB American Depositary Shares in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
27% more funds holding
Funds holding: 11 → 14 (+3)
33% less capital invested
Capital invested by funds: $96.9M → $64.5M (-$32.4M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$4.25M |
| 2 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$542K |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$412K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$286K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$236K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.1M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$6.72M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.45M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.08M |
| 5 |
Jane Street
New York
|
-$256K |
CALT Hedge Fund Activity: Q1 2021 in Review
14 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q1 2021, worth a combined $64.5M — down 33% from $96.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CALT positions and 5 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Endurant Capital Management, opening a new position worth an estimated $4.25M. The largest seller was Logos Global Management, exiting entirely with an estimated $10.1M sold.
- 14 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q1 2021, up from 11 in Q4 2020.
- Funds reported $64.5M of Calliditas Therapeutics AB American Depositary Shares stock for Q1 2021, down 33% quarter-over-quarter.
- 8 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q1 2021 and 5 closed out, a net change of +3 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q1 2021 was Endurant Capital Management, an estimated $4.25M added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q1 2021 was Logos Global Management, an estimated $10.1M sold.
Based on aggregated 13F filings for Q1 2021.